These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 32929261)

  • 1. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders.
    Vollenweider FX; Preller KH
    Nat Rev Neurosci; 2020 Nov; 21(11):611-624. PubMed ID: 32929261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classic Psychedelic Drugs: Update on Biological Mechanisms.
    Vollenweider FX; Smallridge JW
    Pharmacopsychiatry; 2022 May; 55(3):121-138. PubMed ID: 35079988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics.
    Kelmendi B; Kaye AP; Pittenger C; Kwan AC
    Curr Biol; 2022 Jan; 32(2):R63-R67. PubMed ID: 35077687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.
    Kraehenmann R
    Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.
    Gobbi G; Inserra A; Greenway KT; Lifshitz M; Kirmayer LJ
    Transcult Psychiatry; 2022 Oct; 59(5):718-724. PubMed ID: 36263521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
    J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies.
    Breeksema JJ; Niemeijer AR; Krediet E; Vermetten E; Schoevers RA
    CNS Drugs; 2020 Sep; 34(9):925-946. PubMed ID: 32803732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelics and music: neuroscience and therapeutic implications.
    Barrett FS; Preller KH; Kaelen M
    Int Rev Psychiatry; 2018 Aug; 30(4):350-362. PubMed ID: 30240282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.
    Canal CE
    Handb Exp Pharmacol; 2018; 252():227-260. PubMed ID: 29532180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.
    Vollenweider FX; Kometer M
    Nat Rev Neurosci; 2010 Sep; 11(9):642-51. PubMed ID: 20717121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant.
    Sessa B
    Psychopharmacology (Berl); 2018 Feb; 235(2):551-560. PubMed ID: 28831571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity.
    Olson DE
    Biochemistry; 2022 Feb; 61(3):127-136. PubMed ID: 35060714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catalysts for change: the cellular neurobiology of psychedelics.
    Banks MI; Zahid Z; Jones NT; Sultan ZW; Wenthur CJ
    Mol Biol Cell; 2021 Jun; 32(12):1135-1144. PubMed ID: 34043427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroenhancement strategies for psychiatric disorders: rationale, status quo and perspectives.
    Normann C; Nissen C; Frase L
    Eur Arch Psychiatry Clin Neurosci; 2012 Nov; 262 Suppl 2():S113-6. PubMed ID: 22932721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
    Lea T; Amada N; Jungaberle H; Schecke H; Scherbaum N; Klein M
    Psychopharmacology (Berl); 2020 May; 237(5):1521-1532. PubMed ID: 32043165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.
    Greenway KT; Garel N; Jerome L; Feduccia AA
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):655-670. PubMed ID: 32478631
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.